The latest of Teradata’s industry LDMs will benefit life sciences (including pharmaceutical) companies as they integrate, centralize and analyze data used across the business.
The LS-LDM (developed to closely align with CDISC and HL7 industry standards) accelerates answers to questions about sales, marketing, finances, clinical research and supply chain.
Teradata vice president (industry marketing and solutions) John Burke said the company is responding to the growing demand for data warehousing and reinforcing its commitment in the life sciences industry by introducing the LS-LDM.
"Teradata’s LS-LDM addresses the need to define data standards that will enable new business models, deliver higher-return drug portfolios, enable data sharing and accelerate the new drug application (NDA) process," Burke said.
The clinical extension of the LS-LDM is a BRIDG-based logical data model designed to increase clinical trial ROI by improving clinical trial decision-making.